Second, the field needs systematic testing whether targeting specific m6A nodes (e.g., YTHDF2 in TAMs or IGF2BP2/3 at the tumor–endothelium interface) leads to vessel normalization and improved antigen trafficking—alone or combined with anti-VEGF and checkpoint blockade. The gene discussed is IGF2BP2; the disease is neoplasm.